Free Trial

Alkermes (ALKS) Competitors

Alkermes logo
$26.53 -0.66 (-2.43%)
Closing price 04:00 PM Eastern
Extended Trading
$26.95 +0.42 (+1.58%)
As of 06:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ALKS vs. ABEO, MEDP, OMCL, AMN, BIIB, INCY, UTHR, NBIX, EXEL, and BMRN

Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Abeona Therapeutics (ABEO), Medpace (MEDP), Omnicell (OMCL), AMN Healthcare Services (AMN), Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector.

Alkermes vs. Its Competitors

Abeona Therapeutics (NASDAQ:ABEO) and Alkermes (NASDAQ:ALKS) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.

80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by insiders. Comparatively, 4.4% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Alkermes had 13 more articles in the media than Abeona Therapeutics. MarketBeat recorded 16 mentions for Alkermes and 3 mentions for Abeona Therapeutics. Alkermes' average media sentiment score of 0.47 beat Abeona Therapeutics' score of -0.55 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abeona Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Negative
Alkermes
3 Very Positive mention(s)
3 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Alkermes has higher revenue and earnings than Abeona Therapeutics. Abeona Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Abeona Therapeutics$3.50M97.20-$63.73M-$1.27-5.24
Alkermes$1.56B2.81$367.07M$2.0912.69

Abeona Therapeutics presently has a consensus price target of $19.25, suggesting a potential upside of 189.47%. Alkermes has a consensus price target of $40.92, suggesting a potential upside of 54.23%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, research analysts clearly believe Abeona Therapeutics is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abeona Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Alkermes
0 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.83

Alkermes has a net margin of 23.30% compared to Abeona Therapeutics' net margin of 0.00%. Alkermes' return on equity of 27.52% beat Abeona Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Abeona TherapeuticsN/A -118.82% -52.48%
Alkermes 23.30%27.52%17.98%

Abeona Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Summary

Alkermes beats Abeona Therapeutics on 12 of the 17 factors compared between the two stocks.

Get Alkermes News Delivered to You Automatically

Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ALKS vs. The Competition

MetricAlkermesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.48B$3.06B$5.70B$9.48B
Dividend YieldN/A2.37%4.59%3.99%
P/E Ratio12.6920.7327.9019.95
Price / Sales2.81321.07442.18102.66
Price / Cash10.2643.2336.5558.97
Price / Book2.938.308.635.90
Net Income$367.07M-$55.19M$3.24B$258.42M
7 Day Performance-9.64%5.07%3.22%1.94%
1 Month Performance-9.61%17.61%10.72%12.02%
1 Year Performance0.08%7.03%34.94%20.81%

Alkermes Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
4.7768 of 5 stars
$26.53
-2.4%
$40.92
+54.2%
+8.8%$4.48B$1.56B12.691,800Upcoming Earnings
Analyst Forecast
ABEO
Abeona Therapeutics
3.6772 of 5 stars
$5.92
+3.1%
$19.25
+225.2%
+30.8%$302.87M$3.50M-4.6690
MEDP
Medpace
3.9576 of 5 stars
$320.36
-1.0%
$344.82
+7.6%
+22.4%$9.21B$2.11B24.455,900Trending News
Earnings Report
Analyst Forecast
OMCL
Omnicell
3.7603 of 5 stars
$27.57
-3.9%
$44.83
+62.6%
-4.2%$1.29B$1.14B59.943,670Positive News
Upcoming Earnings
Analyst Forecast
AMN
AMN Healthcare Services
4.3022 of 5 stars
$20.72
-2.1%
$32.08
+54.8%
-65.8%$793.27M$2.85B-4.792,968
BIIB
Biogen
4.9303 of 5 stars
$133.11
-0.8%
$188.48
+41.6%
-41.6%$19.50B$9.68B13.147,605Upcoming Earnings
Analyst Upgrade
INCY
Incyte
4.5897 of 5 stars
$69.98
+2.0%
$74.47
+6.4%
+7.4%$13.55B$4.24B218.692,617Upcoming Earnings
Insider Trade
UTHR
United Therapeutics
4.9901 of 5 stars
$297.68
+0.7%
$383.08
+28.7%
-9.2%$13.43B$2.88B11.881,305Positive News
Upcoming Earnings
Analyst Revision
NBIX
Neurocrine Biosciences
4.4634 of 5 stars
$135.13
+1.3%
$163.91
+21.3%
-8.1%$13.37B$2.41B45.811,800Upcoming Earnings
Analyst Forecast
EXEL
Exelixis
4.8166 of 5 stars
$45.58
+1.6%
$45.22
-0.8%
+102.1%$12.43B$2.17B20.721,147Analyst Forecast
BMRN
BioMarin Pharmaceutical
4.9779 of 5 stars
$58.23
+0.2%
$93.78
+61.1%
-29.3%$11.17B$2.85B21.653,040Analyst Forecast
Analyst Revision

Related Companies and Tools


This page (NASDAQ:ALKS) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners